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The influence of synaptic activity on neuronal health
Karen F. S. Bell1 and Giles E. Hardingham1,*
1Centre for Integrative Physiology, University of Edinburgh, Edinburgh EH8 9XD, UK.
Abstract
According to the theory of neuronal health, neurons exist in a spectrum of states ranging from
highly resilient to vulnerable. An unhealthy neuron may be rendered dysfunctional or non-viable
by an insult that would ordinarily be non-toxic to a healthy neuron. Over the years it has become
clear that a neuron’s health is subject to dynamic regulation by electrical or synaptic activity. This
review highlights recently identified activity dependent signalling events which boost neuronal
health through the transcriptional control of pro- and anti-apoptotic genes, the enhancement of
antioxidant defences, and the regulation of mitochondrial and neurotrophic factor availability.
Furthermore, activity dependent signals have recently been shown to influence a variety of events
specific to individual neurodegenerative diseases, which will also be highlighted.
Introduction
Neuronal health is more complex than that offered by the binary classification of either dead
or alive. It is better considered a dynamic spectrum of physiological states ranging from
protected and fully functional to vulnerable and dysfunctional [1]. A neuron’s position
within this spectrum can be influenced by both detrimental and beneficial external cues
(Figure 1). The concept that electrical activity promotes neuronal health, originated from
studies in which activity blockade (either pharmacological or through deafferentation)
caused death in the disconnected target neurons [2].
In vivo studies on the chick and later mammalian developing retinotectal/retino-superior
collicular pathway revealed that neuronal survival required firing activity, as similarly seen
in other systems such as the spiral ganglion [3,4]. Activity-dependent neuroprotection also
appears relevant to mature neurons, despite this being difficult to assess in many brain
regions given the complexity of incoming afferents. Deafferentation of adult cerebellar
granule cells promotes apoptosis, and olfactory bulb ablation triggers deafferentation
dependent apoptosis in piriform cortical neurons[2]. Activity-dependent survival has been
recapitulated in multiple cultured neuronal types including those from the spinal cord,
cerebellum (granule cells and Purkinje cells) hippocampus, neocortex, hypothalamus and
several sensory ganglia [2]. Artificial manipulation of neuronal electrical activity both in
vivo (principally spiral ganglion and retinal ganglion cells) and in culture also promotes
neuronal survival in a variety of experimental systems and trauma models, including models
of apoptosis, oxidative stress and excitotoxicity/ischemia [2,3,5-7].
Ca2+ influx is a key mediator of activity-dependent health-promoting pathways, and the
synaptic N-methyl-D-aspartate receptor (NMDAR) is an important route for such influx.
Impaired synaptic NMDAR activity promotes neuronal death in vitro and in vivo in
development [8,9], in adults NMDAR blockade exacerbates neuronal loss during ongoing
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neurodegeneration or post traumatic brain injury [10] and impairs survival of new-born
neurons in the dentate gyrus [11]. The protective effects of physiological patterns of
synaptic NMDAR activity are in marked contrast to the destructive effects of excessive
NMDAR activity, particularly that mediated by extrasynaptic NMDARs [12,13].
Other sources of activity-dependent Ca2+ elevation are also relevant to neuroprotective
signaling, including release from internal stores [14], as well as firing activity promoting
influx through voltage-gated Ca2+ channels [15], indeed, different sources may cooperate in
the creation of the transient. As will be discussed, neuronal activity triggers neuroprotection
through the complimentary and coincident regulation of numerous health-promoting
pathways that alter vulnerability to apoptotic, excitotoxic and oxidative insults, as will be
outlined below. We will also discuss the emerging role of synaptic activity in influencing a
number of processes specific to individual neurodegenerative diseases.
Synaptic activity induces expression of survival genes and suppresses
pro-death genes
Neuronal activity and resultant Ca2+ influx is an important mechanism of dialogue between
the synapse and nucleus, enabling both activation of second messengers and gene
transcription. Activity-dependent induction of gene expression mediated by the transcription
factor CREB is a classic example of an activity dependent health promoting process which
confers resistance to both apoptotic and excitotoxic insults [16-18]. More recently, a group
of genes termed the activity-regulated inhibitors of death (AID), with visible neuroprotective
effects both in vitro and in vivo, were identified as being activity and nuclear Ca2+ regulated
[19]. Some of these genes appear to be CREB targets, possibly promoting protection through
an enhancement of mitochondrial resistance to stress or toxicity [19]. The Ca2+ responsive
transcription factor NFAT (nuclear factor of activated T cells), was also recently implicated
in NMDAR-dependent neuroprotection [20]. In addition to nuclear Ca2+ signalling, other
neuroprotective signalling cascades are also triggered at the synaptic NMDAR, including the
PI3K-Akt and Erk1/2 pathways [9], and the more recently identified nitric oxide synthase/
Erk dependent activation of neuroprotective transcription factor NFI-A (nuclear factor I
subtype A [21]). NFI-A joins CREB as a transcription factor implicated in mediating both
NMDAR-dependent neuroprotection, as well as conferring resistance to NMDAR-dependent
excitotoxicity.
Neuronal activity is also intimately involved in regulating the expression, processing,
transport and release of neurotrophic factors, many of which have well-characterized
neuroprotective effects. In vivo electrical stimulation upregulates fibroblast growth factor 2
(Fgf2) [22] and delays photoreceptor death, preserving retinal function [23], and also
promotes IGF-1 secretion by Mueller glia. Elevated expression and release of BDNF is
associated with elevated synaptic activity which contributes to neuroprotection [12,24,25],
and BDNF is up-regulated by environmental enrichment in vivo [26]. The release and
maturation of pro-NGF has also been identified as being activity-dependent [27]. Moreover,
activity also promotes growth factor trafficking from the periphery in the case of IGF-1,
enabling a coordinated delivery of trophic support to active areas [28].
In addition to pro-survival gene induction, synaptic activity results in the transcriptional
suppression of core components of the intrinsic apoptotic cascade including Puma, Apaf1,
Casp9, Casp3, and Trp53, leading to enhanced resistance to apoptotic insults [29,30]. While
Puma suppression is central to apoptosis prevention, by preventing insult-induced
cytochrome c release, additional downstream mechanisms such as the downregulation of
Apaf-1 and caspase-9 also exist [29,30]. The transcriptional suppression of these apoptotic
genes may be linked to the activity-dependent inactivation of the transcription factors that
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control their expression, including p53 and the forkhead box protein O (FOXO) class of
transcription factors [29,31,32]
Given that apoptotic features are found in a number of neurodegenerative conditions
including Alzheimer’s, Parkinson’s and Huntington’s diseases (AD, PD, HD respectively),
the above findings are of clinical relevance, highlighting the possibility that less active
neurons are more likely to undergo apoptosis in these conditions. Activity-dependent
caspase regulation may be particularly relevant to AD as non-apoptotic, caspase-dependent
events have been observed in several aspects of the pathology. Caspases have been shown to
cleave the presenilin-1 subunit of γ-secretase, creating a complex which preferentially
releases a higher yield of the more toxic 42-form of Aβ [33]. Moreover, caspases are
activated following Death Receptor 6 binding by an APP cleavage product, leading to
caspase-dependent axonal and cell body degeneration [34]. Caspase activation has also been
linked to both tangle formation [35] and synaptic dysfunction [36] in animal models of AD.
Given that neurodegeneration is a characteristic feature of AD, disrupted neuronal activity
might be a contributing factor to resultant pathology through any of the above described
mechanisms or through enhanced vulnerability to apoptosis itself. It should however be
noted that caspases can mediate important non-apoptotic physiological events, including
forms of long term depression and AMPA receptor internalization which rely on caspase-3
activation [37]. As such, the fact that the Casp3 gene is itself subject to activity-dependent
inactivation [30] may be relevant to physiological as well as pathological processes.
As well as restricting the apoptotic potential of neurons, synaptic activity also boosts
neuronal health through an enhancement of intrinsic antioxidant defences. Previously active
neurons withstand oxidative insults better than less active neurons, a mechanism which at
least partially involves changes within the thioredoxin/peroxiredoxin antioxidant system [6].
Synaptic NMDAR activity reduces the level of oxidant-induced peroxiredoxin
hyperoxidation and enhances expression of sulfiredoxin 1 (Srxn1) and sestrin 2 (Sesn2), the
genes whose products are believed to mediate this. Interestingly, in addition to boosting
expression of these genes, synaptic NMDAR activity also suppresses the expression of the
thioredoxin inhibitor Txnip, a FOXO target gene [6]. Also relevant to the control of
antioxidant defences is the influence of synaptic activity on gene expression promoted by
the co-activator peroxisome proliferator-activated receptor-γ co-activator 1α (PGC-1α), a
master regulator of neuronal antioxidant defences [38,39]. Synaptic activity post-
translationally enhances the transactivating potential of PGC-1α, induces transcription of the
PGC-1α gene, and triggers the nuclear export of the corepressor SMRT [40] which, when
nuclear, can block the antioxidant effects of PGC-1α [39].
Activity dependent regulation of mitochondrial availability and
mitochondria related genes
Neuronal health is influenced by energy demands and Ca2+ homeostasis, two events which
are regulated by mitochondria. By regulating mitochondrial fission/fusion and intracellular
trafficking, neuronal activity triggers events which balance energy demands with localized
availability [41]. For example, synaptic activity enhances mitochondrial fission, reduces
mitochondrial mobility and localizes mitochondria to dendritic spines [42-44] and
presynaptic sites [45] where energy demands are high, as is in line with the finding that
mitochondrial mobility is accelerated in areas rich in ATP and slowed in areas high in ADP
[46].
One mechanism through which mitochondria detect changes in intracellular Ca2+ and
subsequently alter movement, involves the GTPase Miro, which has two EF-hand Ca2+
binding domains. Following Ca2+ influx, Miro unhinges mitochondria from transport
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machinery, enabling stoppage in specific areas [45,47,48]. Mitochondrial movement into
dendritic spines and filopodia is also activity-dependent and is mediated by Wiskott-Aldrich
syndrome protein (WASP)-family verprolin homologous protein 1 (WAVE1) whose
inhibitory phosphorylation by Cdk5 is in turn suppressed by NMDAR activity [49]. In
addition to motility, neuronal activity also promotes gene transcription which enhances
mitochondrial health, such as the previously mentioned activation of AID genes [19] or
PGC1α [39] which is capable of controlling mitochondrial biogenesis [50].
Neuronal activity can influence aspects of disease pathology
We have hitherto focused on general neuroprotective events triggered by neuronal activity,
which may be relevant to the survival of neurons in response to a variety of insults (Figure
2). However, recent studies have illustrated how activity can inhibit molecular events
specific to individual neurodegenerative disease processes (Figure 3). As such, neuronal
hypo-activity could be an exacerbating factor in certain diseases and since this could also be
a consequence of disease pathology, could form a feed-forward cycle of disease progression.
Alzheimer’s Disease
Neuronal activity, specifically that involving synaptic NMDAR activation, appears to have a
suppressive effect on multiple aspects of AD-related amyloid processing. Synaptic NMDAR
activation promotes protective non-amyloidogenic processing, over amyloidogenic
processing, as seen by the activity-dependent recruitment of putative α-secretase ADAM-10
[51], increased non-amyloidogenic pathway components c83 and soluble APPα [52],
reduced Aβ production and release [51,52], reduced APP695 mRNA expression [53] and
reduced intraneuronal Aβ [54]. Interestingly, synaptic activity blockade in vivo in a
transgenic mouse model of AD increased intraneuronal Aβ, reduced synaptophysin-
immunoreactivity, increased synapse loss and worsened behaviour [55], highlighting the
importance of neuronal activity in ameliorating pathology. Adrenergic neuronal activity may
also be relevant, as β2 adrenergic receptor activation enhances glial Aβ uptake and
degradation [56]. One can envisage that any stochastic or disease-related reduction in
neuronal activity could worsen neuronal health and accelerate pathogenesis through the
removal of the above-mentioned brakes on Aβ-related pathology.
Spinal Muscular Atrophy and Amyotrophic Lateral Sclerosis
Both Spinal Muscular Atrophy (SMA) and Amyotrophic Lateral Sclerosis (ALS) are
characterized by degeneration of motor neurons, an event which is influenced by modest
levels of NMDAR activity. In a transgenic mouse model of SMA, exercise was found to
delay motor neuron death, and upregulate NMDAR subunit NR2A, an effect which was
ablated by NMDAR inhibition [57]. Daily in vivo NMDA administration to transgenic
SMA-like mice, accelerated postnatal skeletal muscle maturation, reduced motor neuron
death, improved neuromuscular junction morphology and motor behaviour and prolonged
lifespan [58]. In an ALS-like transgenic mouse model, significant decreases in both NR2A
and αCaMKII autophosphorylation were identified with coincident alterations in synaptic
plasticity and reduced dendritic outgrowth, prior to symptom onset [59], alterations which
led the authors to suggest that reduced glutamatergic signaling may contribute to disease
pathogenesis.
Hungtington’s Disease
Neuronal activity has also been shown to profoundly impact HD pathology, as largely
demonstrated through the use of the YAC 128 HD mouse model. Synaptic activity increased
formation of non-toxic mutant huntingtin (mtHtt) inclusions [60] via the NMDA-dependent
transcriptional upregulation of chaperonin TRiC (T complex-1 (TCP-1) ring complex),
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which mediates non-toxic inclusion formation in neurons, rendering neurons more resistant
to mtHtt-mediated death [60]. Synaptic activity also enhances regulation of CREB target
gene PGC1α, a co-activator which, as previously mentioned, regulates mitochondrial
density and antioxidant defences [38,39,50], and which is lowered in the striatum of HD
patients [61], an area particularly vulnerable to PGC1α deficiency [62]. Interestingly, mtHtt
directly interferes with CREB-dependent PGC1α expression, leading to mitochondrial
dysfunction and metabolic defects [61,63]. Blocking synaptic activity decreases both CREB
activity and PGC1α protein levels, while activation has the opposite effect, suggesting a
mechanism whereby synaptic NMDAR activity enhances neuronal health and resilience to
insult via the protective CREB-PGC1α pathway and promotion of mtHtt inclusion
formation [60]. Extrasynaptic NMDA receptor activation has been known for some time to
dominate over protective CREB dependent signalling originating from synaptic NMDAR
[12,13]. This is particularly relevant given that the YAC 128 mouse model displays an
increase in extrasynaptic NMDAR expression and currents, along with an associated
decrease in CREB activity [64]. Thus, the beneficial effects of synaptic NMDAR activity are
negated by increased, dominating pro-death signalling from extrasynaptic NMDAR.
Interestingly, in vivo low-dose memantine administration, which preferentially blocks
extrasynaptic NMDAR while preserving synaptic NMDAR signalling [65], improved
neuropathological and behavioural outcomes [60,64]. In contrast, higher doses of
memantine, which also block synaptic NMDARs, exacerbated disease pathology and
symptoms [60] highlighting the importance of maintaining synaptic activity to neuronal
health and viability.
Conclusions
The myriad routes by which neuronal activity influences neuronal health are becoming
clearer. Not only are general antioxidant, mitochondrial and apoptotic pathways subject to
control, they are also central to a number of neurodegenerative diseases. Knowledge of such
endogenous neuroprotective pathways points to ways in which they may be mimicked or
boosted for therapeutic effect. Furthermore, they underline the fact that activity-dependent
signals are important contributors to neuronal robustness and that successful therapies
should leave these beneficial effects intact.
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Figure 1.
Neurons exist within a dynamic spectrum of health ranging from vulnerable to resilient as
shown by the red to blue gradients. A neuron’s position within this spectrum is constantly
influenced by a multitude of both beneficial and detrimental cues. In (A), we see that the
weight of an “INSULT”, which represents a variety of detrimental events [e.g. oxidative
stress, excitotoxicity, ischemia, pathology-associated burdens (amyloid beta protein, mutant
huntingtin etc.)], burdens the neuron such that health is compromised and it is rendered
vulnerable. In (B) however, neuronal activity, as represented by an active and muscular
neuron, is able to boost neuronal health, enabling the neuron to withstand the same
“INSULT” burden, whilst remain resilient, emphasizing the important neuroprotective
influence of activity on neuronal health.
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Figure 2.
Schematic demonstrating the mechanisms through which synaptic activity boosts neuronal
health, enabling the cell to better resist dysfunction or death. For full description see text.
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Figure 3.
Neuronal activity has been shown to influence specific disease processes in a number of
experimental models of neurodegenerative disease. Summarized in graphic format are
disease-specific pathways reported as being influenced by neuronal activity, in experimental
models of Alzheimer’s disease (AD), Huntington’s disease (HD) and Spinal Muscular
Atrophy (SMA), as reviewed in greater detail in the text. Aβ = amyloid beta protein, APP =
amyloid precursor protein, mtHtt = mutant Huntingtin, NMJ = neuromuscular junction,
PGC1α = peroxisome proliferator-activated receptor-γ co-activator 1α, sAPPα = soluble
Amyloid Precursor Protein alpha, TriC = T complex-1 (TCP-1) ring complex.
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